All over body with itching
prurigo nodularis multiple papules nodules all over body itching
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 5916
papular urticaria scabies nodular lesions arms itching differential diagnosis
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 3897
| Feature | Observation |
|---|---|
| Lesion type | Dome-shaped firm papules/nodules |
| Surface | Some with white/hyperkeratotic tops (excoriated/crusted) |
| Distribution | Extensor arms, spreading proximally and distally |
| Background skin | Post-inflammatory hyperpigmentation |
| Symptom | Intense generalized pruritus |

| Condition | Distinguishing Features |
|---|---|
| Nodular scabies | Burrows in web spaces/genitalia; household contacts affected; responds to scabicides |
| Papular urticaria | Urticarial base, insect bite history, transient lesions |
| Lichen planus | Violaceous flat-topped papules, Wickham striae, oral lesions |
| Hypertrophic lichen planus | Thick plaques on shins, overlapping features with PN |
| Pemphigoid nodularis | Rare; blister formation; IgG/C3 on IF |
Important: In any new or severe case of PN, screen for underlying systemic triggers (see below), especially given the widespread distribution.
| Category | Tests |
|---|---|
| Renal | BUN, creatinine (CKD is a major cause) |
| Hepatic | LFTs, HBsAg, anti-HCV (cholestatic itch) |
| Haematologic | CBC, peripheral smear (polycythemia vera, lymphoma) |
| Endocrine | TFTs (thyroid disease), FBS (diabetes) |
| Infectious | HIV serology (PN is a well-known HIV-associated dermatosis — Harrison's, p. 5916) |
| Atopic | IgE, eosinophil count (atopic diathesis) |
| Iron stores | Serum ferritin, iron studies |
| Drug | Dose | Notes |
|---|---|---|
| Antihistamines | Cetirizine/hydroxyzine | Adjunct for itch relief |
| Gabapentin/pregabalin | 300–1800 mg/day | For neuropathic itch component |
| Naltrexone (low-dose) | 4.5 mg/night | Opioid antagonist for refractory pruritus |
| Dupilumab | 300 mg SC every 2 weeks | IL-4/IL-13 blockade; FDA-approved for PN (2022) |
| Thalidomide/lenalidomide | Specialist use | For severe refractory PN |
| Narrowband UVB phototherapy | 2–3×/week | Effective for widespread disease |